Does Rallies show Form 4 insider transactions for PSTV?

Yes. Rallies tracks PSTV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PSTV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PSTV. It does not provide personalized investment advice.

PSTV (PLUS THERAPEUTICS, Inc. Common Stock) Stock Analysis - Insider Trades

PLUS THERAPEUTICS, Inc. Common Stock (PSTV) is a publicly traded Healthcare sector company. As of May 19, 2026, PSTV trades at $5.89 with a market cap of $36.03M and a P/E ratio of -19.12. PSTV moved +3.85% today. Year to date, PSTV is -57.91%; over the trailing twelve months it is -44.38%. Its 52-week range spans $2.90 to $57.75. Analyst consensus is strong buy with an average price target of $38.00. Rallies surfaces PSTV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PSTV stock inside the company?

Recent PSTV insider activity includes Sims Andrew John Hugh MacIntyre bought 20.00K, Lenk Robert P bought 110.00K, Hawkins Richard J bought 4.00K, Hawkins Richard J bought 6.29K, and Petersen Greg bought 12.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PSTV Key Metrics

Key financial metrics for PSTV
Metric	Value
Price	$5.89
Market Cap	$36.03M
P/E Ratio	-19.12
EPS	$-0.29
Dividend Yield	0.00%
52-Week High	$57.75
52-Week Low	$2.90
Volume	96.84K
Avg Volume	0
Revenue (TTM)	$5.21M
Net Income	$-22.39M
Gross Margin	0.00%

Recent PSTV Insider Trades

Sims Andrew John Hugh MacIntyre bought 20.00K (~$10.20K) on Nov 4, 2025.
Lenk Robert P bought 110.00K (~$53.78K) on Aug 22, 2025.
Hawkins Richard J bought 4.00K (~$6.00K) on Sep 13, 2024.
Hawkins Richard J bought 6.29K (~$8.51K) on Sep 12, 2024.
Petersen Greg bought 12.50K (~$16.88K) on Sep 11, 2024.

Latest PSTV News

Plus Therapeutics Deploys AI Platform for CNS Oncology Data Integration Starting 2026 — May 19, 2026
Plus Therapeutics Raises $15M, Expands CNSide Coverage to 81M Lives, Gains FDA Orphan Status — May 15, 2026
Plus Therapeutics Secures Medicare Enrollment, Unlocks Billing for CNSide Assay to 35M Patients — May 7, 2026
Plus Therapeutics Expands CNSide Coverage by 6 Million Lives to 81 Million with Blue Shield Deal — Apr 28, 2026
Plus Therapeutics Initiates SpectronRx Manufacturing for REYOBIQ Late-Stage Trial Readiness — Apr 23, 2026

PSTV Analyst Consensus

5 analysts cover PSTV: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $38.00.

Common questions about PSTV

Who is trading PSTV stock inside the company?: Recent PSTV insider activity includes Sims Andrew John Hugh MacIntyre bought 20.00K, Lenk Robert P bought 110.00K, Hawkins Richard J bought 4.00K, Hawkins Richard J bought 6.29K, and Petersen Greg bought 12.50K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PSTV?: Yes. Rallies tracks PSTV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PSTV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PSTV. It does not provide personalized investment advice.